Status:
TERMINATED
Compensatory Reserve Index (CRI) for Management of COVID-19
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
Children's Hospital Colorado
Conditions:
COVID
Eligibility:
All Genders
18-70 years
Brief Summary
The FDA has approved the CipherOx CRI T1 Tablet for use in subjects aged 19-36, and that this study aims to evaluate the device in subjects aged outside of this range and is being used off label. The...
Eligibility Criteria
Inclusion
- Eligible patients will be those who are:
- COVID-19 positive;
- Ages \> 18 and \< 70 years old;
- Require \> 2 liters of oxygen by nasal cannula to maintain SpO2 \> 90%;
- Are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service).
Exclusion
- COVID-19 negative
- Age \<18 or \>70 years
- On \<2 liters oxygen via nasal canula
- Pregnant
- Incarcerated
- DNR/DNI
- Decisionally Challenged
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 8 2021
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT04457817
Start Date
December 1 2020
End Date
April 8 2021
Last Update
November 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado
Aurora, Colorado, United States, 80045